- Home
- BTOG vs TENX Comparison
BTOG vs TENX Comparison
Compare BTOG & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTOG
- TENX
- Stock Information
- Founded
- BTOG 2018
- TENX 1967
- Country
- BTOG Singapore
- TENX United States
- Employees
- BTOG N/A
- TENX N/A
- Industry
- BTOG Finance: Consumer Services
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- BTOG Finance
- TENX Health Care
- Exchange
- BTOG Nasdaq
- TENX Nasdaq
- Market Cap
- BTOG 11.0M
- TENX 11.4M
- IPO Year
- BTOG 2019
- TENX N/A
- Fundamental
- Price
- BTOG $1.37
- TENX $4.88
- Analyst Decision
- BTOG
- TENX Strong Buy
- Analyst Count
- BTOG 0
- TENX 4
- Target Price
- BTOG N/A
- TENX $20.67
- AVG Volume (30 Days)
- BTOG 126.1K
- TENX 96.7K
- Earning Date
- BTOG 01-01-0001
- TENX 11-13-2024
- Dividend Yield
- BTOG N/A
- TENX N/A
- EPS Growth
- BTOG N/A
- TENX N/A
- EPS
- BTOG N/A
- TENX N/A
- Revenue
- BTOG $7,088,763.00
- TENX N/A
- Revenue This Year
- BTOG N/A
- TENX N/A
- Revenue Next Year
- BTOG N/A
- TENX N/A
- P/E Ratio
- BTOG N/A
- TENX N/A
- Revenue Growth
- BTOG 214.61
- TENX N/A
- 52 Week Low
- BTOG $1.28
- TENX $2.77
- 52 Week High
- BTOG $9.71
- TENX $33.44
- Technical
- Relative Strength Index (RSI)
- BTOG 32.23
- TENX 62.62
- Support Level
- BTOG $1.38
- TENX $4.50
- Resistance Level
- BTOG $2.29
- TENX $5.09
- Average True Range (ATR)
- BTOG 0.28
- TENX 0.27
- MACD
- BTOG -0.04
- TENX 0.00
- Stochastic Oscillator
- BTOG 8.91
- TENX 73.42
About BTOG Bit Origin Limited
Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.